While the pathological Ser40 mutation has not been identified in patient databases, these findings suggest that clinical SPOP mutations could lead to aberrant PrLZ accumulation, driving tumor progression and contributing to poor outcomes in PCa patients. The gene discussed is TPD52; the disease is posterior cortical atrophy.